Activism Archives – Page 2 of 6 – Treatment Action Group

Mourning Paul Farmer, Honoring His Legacy

February 23, 2022
Dorrit Walsh

TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.

An Activist’s Guide to Shorter Treatment for Drug-Sensitive Tuberculosis

October 26, 2021
Dorrit Walsh

After a decades-long wait, shorter treatment for drug-sensitive tuberculosis (TB) for adults and children is finally possible. Two landmark clinical trials (S31/A5349 and SHINE) have demonstrated that adults, adolescents, and some children can be cured of TB in as little as four months.

graphic from Breaking Barriers summary that shows why covid-19 and HIV remain prevalent in U.S. communities of color - structural racism pathways are: income, homelessness, unemployment, residental segregation, insurance-healthcare access, incarceration, provider bias, federal laws, and local policies

TAG and COVID-19 Prevention Network Fact Sheets

October 19, 2021
Dorrit Walsh

These three fact sheets were developed by TAG in partnership with the COVID-19 Prevention Network (CoVPN) and the Black AIDS Institute (BAI), and they aim to foster community understanding of COVID-19 vaccine research and development, as well as highlight community perspectives on the topic.

Statement from TAG’s TB Project on Today’s WHO Global TB Report

October 14, 2021
Dorrit Walsh

Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.

A Partnership to Expand Access to Lifesaving Testing and Treatment for Hepatitis C

September 20, 2021
Dorrit Walsh

Hepatitis C PACT was launched in 2021 and aims to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus (HCV) in low-and middle-income countries (LMICs), home to 75% of people living with the viral illness. This brief explains the group's goals and work.

first page of TAG and MSF brief: Realizing returns on U.S. government investment in GeneXpert Diagnostic Technologies

Realizing Returns on U.S. Government Investments in GeneXpert Diagnostic Technologies

September 15, 2021
Dorrit Walsh

GeneXpert diagnostic tests are essential tools in the struggle against COVID-19, tuberculosis, HIV, viral hepatitis, and other diseases. This brief outlines actionable steps the U.S. government can take to hold Cepheid accountable for transparent, fair, and equitable pricing of GeneXpert tests.

Have a Heart, Save My Liver! Who Has Access to the Cure in Africa?

September 11, 2021
Dorrit Walsh

On September 11 2021, Treatment Action Group’s Joelle Dountio Ofinboudem presented new data on the registration of the hepatitis C cure at the Conference on Liver Disease in Africa (COLDA) 2021. The presentation titled, “Have a Heart, Save My Liver! Who Has Access to the Cure in Africa,” explains that accelerating treatment uptake across Africa is urgently needed to meet WHO hepatitis C targets by 2030.

TAG Celebrates TB Advocacy Award for Senior Policy Officer Elizabeth Lovinger

June 25, 2021
Dorrit Walsh

TAG joins the U.S. National TB Controllers Association (NTCA) in celebrating our dedicated and brilliant Senior Government Relations and Policy Officer, Elizabeth (Lizzy) Lovinger, who today received the 2021 Charles DeGraw TB Advocacy Award.

Unique Barriers to COVID-19 Vaccine Access for Black Communities

May 11, 2021
Dorrit Walsh

On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.

The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times

May 10, 2021
Dorrit Walsh

This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.